ENTPD1/CD39 as a Predictive Marker of Treatment Response to Gemogenovatucel-T as Maintenance Therapy in Newly Diagnosed Ovarian Cancer

All patients enrolled in the VITAL trial of maintenance gemogenovatucel-T vs. placebo as front-line therapy with homologous recombination proficient stage IIIB-IV newly diagnosed ovarian cancer underwent NanoString gene expression analysis.